RBFC
TEVA icon

Roman Butler Fullerton & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Roman Butler Fullerton & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,386
Closed -$288K – 177
2019
Q1 		$288K Sell
18,386
-749
-4% -$13.2K 0.2% 143
2018
Q4 		$348K Buy
+19,135
New +$392K 0.3% 113

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Roman Butler Fullerton & Co's TEVA Position: Q2 2019 in Review

Roman Butler Fullerton & Co sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 18,386 shares — an estimated $288K sold.

Roman Butler Fullerton & Co first reported a position in TEVA in Q4 2018 and held it in 2 quarters. The position peaked at $348K in Q4 2018. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Roman Butler Fullerton & Co reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 18,386 Teva Pharmaceuticals shares in Q2 2019, an estimated $288K.
  • Roman Butler Fullerton & Co first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Roman Butler Fullerton & Co's Teva Pharmaceuticals position peaked at $348K in Q4 2018.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2019, filed 22 Jul 2019.